Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
69,351.55
(
0.67%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

randychub

Send PM Follow Ignore
Followers 24
Posts 2702
Boards Moderated 0
Alias Born 10/23/2003

randychub

Re: io_io post# 12508

Friday, 06/24/2005 9:52:16 AM

Friday, June 24, 2005 9:52:16 AM

Post# of 257268
ymi - "surely with a strong survival benefit, the combo will immediately rival taxotere"

Excellent point. The survival benefit in this group of patients, if it lives up to the first phase 3 trial, will be well beyond any other treatment available for these patients. So why not use this combination for all of the patients in this catagory?

R
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today